Reverse transcription polymerase chain reaction

GMED Global Now Offering Rapid COVID-19 PCR Testing in Houston

Retrieved on: 
Wednesday, February 10, 2021

In response to the CDC's travel guidelines and to help travelers meet the requirements for airline travel, GMED Global, LLC, an international health care institution specializing in medical education and health care workforce development and solutions for government and non-government organizations, today announced that it is offering next day PCR testing at both of its Houston Rapid COVID Clinics .

Key Points: 
  • In response to the CDC's travel guidelines and to help travelers meet the requirements for airline travel, GMED Global, LLC, an international health care institution specializing in medical education and health care workforce development and solutions for government and non-government organizations, today announced that it is offering next day PCR testing at both of its Houston Rapid COVID Clinics .
  • Widely regarded as the gold standard in viral testing, Rapid COVID Clinic's next day PCR testing offers travelers convenient, drive through access and highly accurate results with a quick turnaround.
  • PCR testing requirements vary by destination, and GMED recommends that travelers check with their airlines and travel destination to confirm which type of RT-PCR test is approved.
  • The address and operating hours for next-day PCR testing through GMED's Rapid COVID Clinic are as follows:

George Mason University Providing COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform

Retrieved on: 
Wednesday, February 10, 2021

Adoption of the Advanta Dx SARS-CoV-2 RT-PCR Assay is one element of a plan to greatly expand our capacity.

Key Points: 
  • Adoption of the Advanta Dx SARS-CoV-2 RT-PCR Assay is one element of a plan to greatly expand our capacity.
  • A growing body of peer-reviewed research is confirming that the accuracy of saliva-based COVID-19 testing is comparable to that of nasopharyngeal-based testing.
  • Fluidigm continually conducts in silico analyses to determine the effectiveness of the Advanta Dx Assay design to detect SARS-CoV-2.
  • The Advanta Dx SARS-CoV-2 RT-PCR Assay is only for use under the Food and Drug Administration's Emergency Use Authorization.

Syndromic Multiplex Diagnostic Markets, 2025 - COVID-19 Pandemic is Ushering in a New World of Infectious Disease Diagnostics

Retrieved on: 
Tuesday, February 9, 2021

Infectious Disease is Declining But..

Key Points: 

Infectious Disease is Declining But..
Syndrome Testing Moving to Big Instruments?
A Big Future for PCR?

Microbix Announces Material First Sales of Viral Transport Medium

Retrieved on: 
Tuesday, February 9, 2021

MISSISSAUGA, Ontario, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix), a life sciences innovator and exporter, is pleased to announce material first sales of its viral transport medium (generically known as VTM and branded as DxTM) that supports Canadian RT-PCR (molecular) testing for the virus causing COVID-19 disease.

Key Points: 
  • MISSISSAUGA, Ontario, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix), a life sciences innovator and exporter, is pleased to announce material first sales of its viral transport medium (generically known as VTM and branded as DxTM) that supports Canadian RT-PCR (molecular) testing for the virus causing COVID-19 disease.
  • First sales of 50,000 vials (approximately one lot) have now been made to a private-market client at Microbixs targeted pricing for this newly-available product.
  • Microbix remains engaged with the principal supply-chain organization supporting hospitals in Ontario to procure DxTM for testing programs within the province.
  • Cameron Groome, CEO & President of Microbix, remarked, Were honoured to be helping manage the COVID-19 pandemic by making highest-quality viral transport medium here in Ontario.

Thermo Fisher Scientific Launches CE-IVD-Marked High Throughput COVID-19 Diagnostic Assay for Use On Its Automated Amplitude Platform

Retrieved on: 
Monday, February 8, 2021

The highly automated Amplitude platform is a molecular diagnostic system that allows labs to increase their COVID-19 testing capacity by combining Thermo Fisher's extraction and real-time PCR instruments with liquid handling products from Tecan Group.

Key Points: 
  • The highly automated Amplitude platform is a molecular diagnostic system that allows labs to increase their COVID-19 testing capacity by combining Thermo Fisher's extraction and real-time PCR instruments with liquid handling products from Tecan Group.
  • The system leverages a high-throughput version of Thermo Fisher's TaqPath COVID-19 CE-IVD RT-PCR Kit, which received CE-IVD Mark in March 2020.
  • The high throughput diagnostic assay, compatible with the Amplitude platform, also received Interim Order Authorization from Health Canada on January 21.
  • Thermo Fisher has secured a contract with a large provincial authority in Canada for Amplitude systems to help fight the pandemic.

CTR Laboratory Begins COVID-19 Testing in Frederick, Maryland

Retrieved on: 
Thursday, February 4, 2021

FREDERICK, Md., Feb. 4, 2021 /PRNewswire-PRWeb/ --Chesapeake Toxicology Resources, LLC (CTR Labs) is pleased to announce to the Frederick Community its launching of confirmatory testing for COVID-19 (SARS CoV-2) via state-of-the-art rt-PCR testing.

Key Points: 
  • FREDERICK, Md., Feb. 4, 2021 /PRNewswire-PRWeb/ --Chesapeake Toxicology Resources, LLC (CTR Labs) is pleased to announce to the Frederick Community its launching of confirmatory testing for COVID-19 (SARS CoV-2) via state-of-the-art rt-PCR testing.
  • CTR Labs is isolating and amplifying three unique gene fragments as a confirmation threshold ensuring proper identification of the COVID-19 virus.
  • The goal and mission of CTR is to provide superior testing and reporting to the Frederick community within 24-36 hours from sample collection.
  • If you have questions regarding the testing process or reporting options, please call Joe Magluilo or speak to one of the laboratory professionals aby calling 240.397.7060.

Biocept Provides Update on COVID-19 Testing with More than 250,000 Samples Received

Retrieved on: 
Wednesday, February 3, 2021

We continue to serve our community during the pandemic with this important testing and have received nearly 55,000 COVID-19 samples since the beginning of 2021, said Michael Nall, President and CEO of Biocept.

Key Points: 
  • We continue to serve our community during the pandemic with this important testing and have received nearly 55,000 COVID-19 samples since the beginning of 2021, said Michael Nall, President and CEO of Biocept.
  • As previously noted, we expect COVID-19 RT-PCR testing will be a significant component of our business until the pandemic subsides.
  • Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.
  • Additionally, Biocept is offering nationwide COVID-19 polymerase chain reaction (PCR) testing to support public health efforts during this unprecedented pandemic.

QuantuMDx’ Rapid, Sensitive SARS-CoV-2 PCR Test Validated for Use

Retrieved on: 
Wednesday, February 3, 2021

QuantuMDx Group Limited, a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today announces its sensitive SARS-CoV-2 assay for laboratory use has been validated by NHS Test and Trace.

Key Points: 
  • QuantuMDx Group Limited, a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today announces its sensitive SARS-CoV-2 assay for laboratory use has been validated by NHS Test and Trace.
  • QuantuMDxs SARS-CoV-2 assay, which delivers a result in approximately 70 minutes, following preparation and extraction of RNA is a real-time reverse transcriptase PCR (rtRT-PCR) test that has been developed using advanced bioinformatics to maximise performance.
  • The sensitive test targets three unique SARS-CoV-2 specific genomic loci; the S and N genes and the Orf1ab region.
  • QuantuMDx is also independently validating the use of the test without the need for RNA extraction, running the RT-PCR test directly from swabs.

Visby Medical Speeds Development of a Rapid Flu-COVID PCR Test Designed for At-Home Use with BARDA Funding

Retrieved on: 
Tuesday, February 2, 2021

The FDA provided emergency use authorization for Visby Medical's rapid RT-PCR assay to detect the novel coronavirus.

Key Points: 
  • The FDA provided emergency use authorization for Visby Medical's rapid RT-PCR assay to detect the novel coronavirus.
  • This BARDA funding will advance a next-generation device to detect flu and/or COVID-19 in one hand-held rapid PCR test for use at the point-of-need and eventually in consumer's homes as an over-the-counter test.
  • The Visby Medical Flu-COVID PCR Test will offer rapid PCR testing in a single-use, all-in-one device that fits in the palm of your hand.
  • BARDA funding will help Visby Medical speed the development of its PCR Flu-COVID rapid test.